tiprankstipranks
Advertisement
Advertisement

REGN Stock Latest News

Regeneron Stock (REGN) Buckling as Shareholders Sue Over Cancer Drug Claims
Market NewsRegeneron Stock (REGN) Buckling as Shareholders Sue Over Cancer Drug Claims
1d ago
REGN
Regeneron’s Olatorepatide Trial Signals a Bid for Obesity Market Upside
PremiumCompany Announcements
Regeneron’s Olatorepatide Trial Signals a Bid for Obesity Market Upside
2d ago
REGN
Private Markets: $1B for Base Power, $545M for Whatnot
PremiumThe Fly
Private Markets: $1B for Base Power, $545M for Whatnot
2d ago
U
GD
Regeneron’s Pasatru granted FDA approval for FOP
PremiumThe Fly
Regeneron’s Pasatru granted FDA approval for FOP
2d ago
REGN
Regeneron price target raised to $824 from $641 at Leerink
PremiumThe Fly
Regeneron price target raised to $824 from $641 at Leerink
5d ago
REGN
Private Markets: Databricks secures $5B as Kalshi targets $40B valuation
PremiumThe FlyPrivate Markets: Databricks secures $5B as Kalshi targets $40B valuation
5d ago
AI
IBM
The Week That Was, The Week Ahead: Macro and Markets, August 16
Premium
Market News
The Week That Was, The Week Ahead: Macro and Markets, August 16
6d ago
AS
AU
Regeneron Targets Cat Allergy Eye Relief With New Phase 3 Antibody Trial
Premium
Company Announcements
Regeneron Targets Cat Allergy Eye Relief With New Phase 3 Antibody Trial
10d ago
REGN
Regeneron announces Health Canada approval of new indication for Libtayo
PremiumThe Fly
Regeneron announces Health Canada approval of new indication for Libtayo
16d ago
REGN
Regeneron Targets Next‑Gen Cancer Immunotherapy With New Phase 1/2 Trial
PremiumCompany Announcements
Regeneron Targets Next‑Gen Cancer Immunotherapy With New Phase 1/2 Trial
17d ago
REGN
Regeneron price target raised to $1,030 from $1,000 at Guggenheim
PremiumThe Fly
Regeneron price target raised to $1,030 from $1,000 at Guggenheim
19d ago
REGN
Regeneron price target raised to $740 from $700 at Citi
PremiumThe Fly
Regeneron price target raised to $740 from $700 at Citi
19d ago
REGN
Regeneron and Sanofi Terminate Real‑World Dupilumab Study in Chronic Urticaria
PremiumCompany AnnouncementsRegeneron and Sanofi Terminate Real‑World Dupilumab Study in Chronic Urticaria
22d ago
SNY
REGN
Regeneron price target raised to $737 from $696 at RBC Capital
Premium
The Fly
Regeneron price target raised to $737 from $696 at RBC Capital
22d ago
SNY
REGN
Regeneron price target raised to $758 from $730 at Morgan Stanley
Premium
The Fly
Regeneron price target raised to $758 from $730 at Morgan Stanley
22d ago
REGN
Regeneron price target raised to $891 from $856 at BofA
PremiumThe Fly
Regeneron price target raised to $891 from $856 at BofA
22d ago
REGN
Regeneron price target raised to $795 from $750 at Cantor Fitzgerald
PremiumThe Fly
Regeneron price target raised to $795 from $750 at Cantor Fitzgerald
22d ago
REGN
Regeneron price target raised to $761 from $742 at Baird
PremiumThe Fly
Regeneron price target raised to $761 from $742 at Baird
22d ago
REGN
Regeneron price target raised to $750 from $700 at Wells Fargo
PremiumThe Fly
Regeneron price target raised to $750 from $700 at Wells Fargo
22d ago
REGN
Regeneron: Strong Execution, Growth Visibility and Pipeline Catalysts Drive Price Target Increase to $891
PremiumRatingsRegeneron: Strong Execution, Growth Visibility and Pipeline Catalysts Drive Price Target Increase to $891
22d ago
REGN
Regeneron Earnings Call Highlights Dupixent-Driven Surge
Premium
Company Announcements
Regeneron Earnings Call Highlights Dupixent-Driven Surge
23d ago
REGN
Regeneron cuts FY26 CapEx view to $1.03B-$1.1B from $1.1B-$1.2B
Premium
The Fly
Regeneron cuts FY26 CapEx view to $1.03B-$1.1B from $1.1B-$1.2B
23d ago
REGN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >